SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests.

Autor: Kay GA; Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK.; Departments of Vector Biology and Tropical Disease Biology, Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool, UK., Owen SI; Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK., Giorgi E; Centre for Health Informatics Computing and Statistics, Lancaster University Medical School, Lancaster University, Lancaster, UK., Clark DJ; Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK., Williams CT; Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK., Menzies S; Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK., Cuevas LE; Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK., Davies BMO; Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK., Eckersley NM; Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK., Hughes GL; Departments of Vector Biology and Tropical Disease Biology, Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool, UK., Kirwan DE; Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK., Krishna S; Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.; St George's University Hospitals NHS Foundation Trust, London, UK.; Institut für Tropenmedizin, Universitätsklinikum Tübingen, Tübingen, Germany.; Centre de Recherches Médicales de Lambaréné, Lambaréné, Gabon., Patterson EI; Departments of Vector Biology and Tropical Disease Biology, Centre for Neglected Tropical Diseases, Liverpool School of Tropical Medicine, Liverpool, UK.; Department of Biological Sciences, Brock University, St. Catharines, Canada., Planche T; Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK.; St George's University Hospitals NHS Foundation Trust, London, UK., Staines HM; Centre for Diagnostics & Antimicrobial Resistance, Clinical Academic Group in Institute for Infection & Immunity, St George's University of London, London, UK. hstaines@sgul.ac.uk., Adams ER; Centre for Drugs and Diagnostics, Liverpool School of Tropical Medicine, Liverpool, UK. Emily.Adams@lstmed.ac.uk.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2022 Mar 01; Vol. 12 (1), pp. 3351. Date of Electronic Publication: 2022 Mar 01.
DOI: 10.1038/s41598-022-07263-8
Abstrakt: Severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread globally since its emergence in 2019. Most SARS-CoV-2 infections generate immune responses leading to rising levels of immunoglobulins (Ig) M, A and G which can be detected using diagnostic tests including enzyme-linked immunosorbent assays (ELISA). Whilst implying previous SARS-CoV-2 infection, the detection of Ig by ELISA does not guarantee the presence of neutralising antibodies (NAb) that can prevent the virus infecting cells. Plaque reduction neutralisation tests (PRNT) detect NAb, but are not amenable to mass testing as they take several days and require use of SARS-CoV-2 in high biocontainment laboratories. We evaluated the ability of IgG and IgM ELISAs targeting SARS-CoV-2 spike subunit 1 receptor binding domain (S1-RBD), and spike subunit 2 (S2) and nucleocapsid protein (NP), at predicting the presence and magnitude of NAb determined by PRNT. IgG S2 + NP ELISA was 96.8% [95% CI 83.8-99.9] sensitive and 88.9% [95% CI 51.8-99.7] specific at predicting the presence of NAbs (PRNT 80  > 1:40). IgG and IgM S1-RBD ELISAs correlated with PRNT titre, with higher ELISA results increasing the likelihood of a robust neutralising response. The IgM S1-RBD assay can be used as a rapid, high throughput test to approximate the magnitude of NAb titre.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje